Antibody Drug Conjugates: Re-emergence of an old modality for targeted therapies
Explore the key challenges in ADC development and how Syngene, a leading CRO/CDMO, is supporting clients in the discovery, development, and manufacturing of innovative ADC molecules.
How to overcome solubility challenges by applying amorphous solid dispersion: An end-to-end solution
Discover the successful approach to preparing, screening, characterizing, and dosing amorphous solid dispersions (ASDs) in preclinical and early clinical development.
Cracking the Code: Transformative role of pDNA in advanced modalities
Reasons behind the rise in demand for pDNA and what to look for in a pDNA engineering and manufacturing partner when deciding to outsource.
Pharma Supply Chain: From Fragile to Agile
CDMOs bolster supply networks with additional capabilities to make themselves resilient to potential challenges and ensure secure supplies to customers.
Quality management paradigm shift: Risk-centric practices come center stage
CDMOs have moved to risk-based quality management systems comprising highly integrated and digitalized processes powered by data to ensure drug quality.
Protein therapeutics to amp up outsourcing in animal health
With the boom in pet ownership and rising awareness about pet health, veterinary drug makers are betting big on protein therapeutics and outsourcing biologics development to CDMOs.
CROs at the high table of drug discovery
Find out how offshoring has reached an inflection point as CROs turn risk-sharing partners in discovery research.
CMOs bask in pill promise
With sponsors having more oral solid dosage (OSD) products in their pipelines, CMOs anticipate an increasing trend in OSD outsourcing. Find out the criteria to choose the right CMO for OSD outsourcing.
Pharma 4.0: Taking CDMO factories by storm
Contract development manufacturing firms are ramping up the adoption of Pharma 4.0 technologies as regulators and customers increasingly seek transparency and integrity in manufacturing data.
New modalities hog the limelight
Explore how Cell and Gene, mRNA, Bispecifics, and ADCs are turning the tide as CDMOs see service demand for these therapies soar.